The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor?

Acute thrombus formation on disrupted atherosclerotic plaques plays a key role during the onset of acute coronary syndromes. Lesion disruption facilitates the interaction between circulating blood and prothrombotic substances, such as tissue factor (TF) present within the atherosclerotic lesion. For a long period of time, vessel-wall TF has been considered the major determinant of thrombosis. However, this old dogma has been recently changed owing to the discovery of a different pool of TF that circulates in flowing blood (blood-borne TF). Several studies have shown that blood-borne TF circulates in different pools that are associated with selected blood cells, such as monocytes, granulocytes and platelets in cell-derived microparticles, and as a soluble protein generated by alternative splicing of its full-length mRNA. Recent studies have identified a hypercoagulable state associated with an increased circulating TF activity, leading to the concept of ‘vulnerable blood’. Part of the blood-borne TF circulates in an ‘inactive’ form and it is required to be ‘activated’ to exert its thrombogenic potential. Certain pathological conditions, such as smoking, hyperlipidemia and diabetes, show a higher incidence of thrombotic complications. These conditions are also characterized by the presence of high levels of circulating TF activity. Recent evidence may also suggest that an increased circulating TF activity may potentiate the initial thrombogenic stimulus represented by vessel wall-associated TF, leading to the formation of larger and/or more stable thrombus, and thus more severe acute coronary syndromes. It has been reported that inflammation increases TF expression and activity by different cell types. On the other hand, TF upregulation may facilitate inflammation by enhancing intravascular fibrin deposition, formation of proinflammatory fragments of fibrin, and by generating coagulation proteases, including FVIIa, FXa and thrombin, that activate protease-activated receptors. Furthermore, the biology of TF is know known to be more complex than previously thought by the demonstration that this protein, apart from its known effects on blood coagulation, can also function as a signaling receptor.

[1]  P. Libby Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[2]  J. Badimón,et al.  Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited? , 2011, Internal and emergency medicine.

[3]  E. Tremoli,et al.  Tissue factor expression on platelets is a dynamic event. , 2010, Blood.

[4]  K. Mann,et al.  No evidence for tissue factor on platelets. , 2010, Blood.

[5]  H. Versteeg,et al.  Alternatively spliced tissue factor , 2010, Hämostaseologie.

[6]  I. Bernlochner,et al.  A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. , 2010, Journal of the American College of Cardiology.

[7]  H. Versteeg,et al.  Tissue-Faktor nach alternativem Splicing , 2010 .

[8]  E. Jordanova,et al.  Alternatively spliced tissue factor induces angiogenesis through integrin ligation , 2009, Proceedings of the National Academy of Sciences.

[9]  José A López,et al.  Microparticles and thrombotic disease , 2009, Current opinion in hematology.

[10]  A. Kastrati,et al.  Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction , 2009, Thrombosis journal.

[11]  G. Cimmino,et al.  Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay , 2009, Journal of thrombosis and haemostasis : JTH.

[12]  P. Vanhoutte,et al.  Endothelial dysfunction: the first step toward coronary arteriosclerosis. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[13]  J. Hansen,et al.  No evidence for the presence of tissue factor in high‐purity preparations of immunologically isolated eosinophils , 2008, Journal of thrombosis and haemostasis : JTH.

[14]  A. Balduini,et al.  Tissue Factor in Patients with Acute Coronary Syndromes. Expression In , 2022 .

[15]  W. Fay,et al.  C-Reactive Protein Enhances Tissue Factor Expression by Vascular Smooth Muscle Cells: Mechanisms and In Vivo Significance , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[16]  E. Egorina,et al.  Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. , 2008, Blood.

[17]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[18]  A. Weltermann,et al.  Circulating tissue factor-exposing microparticles. , 2008, Thrombosis research.

[19]  Y. Castier,et al.  Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. , 2007, Journal of the American College of Cardiology.

[20]  M. Hellum,et al.  Calcium ionophore-induced de-encryption of tissue factor in monocytes is associated with extensive cell death. , 2007, Thrombosis research.

[21]  Nigel Mackman,et al.  Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets , 2006, The Journal of experimental medicine.

[22]  E. Tremoli,et al.  Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation 1 , 2006, Journal of thrombosis and haemostasis : JTH.

[23]  A. Chu Tissue factor upregulation drives a thrombosis–inflammation circuit in relation to cardiovascular complications , 2006, Cell biochemistry and function.

[24]  E. Bjørklid,et al.  Sources of tissue factor. , 2006, Seminars in thrombosis and hemostasis.

[25]  R. Bach,et al.  Tissue factor encryption. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Chiariello,et al.  C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. , 2005, Cardiovascular research.

[27]  A. Chu Tissue factor mediates inflammation. , 2005, Archives of biochemistry and biophysics.

[28]  Ildikó Kriszbacher,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, New England Journal of Medicine.

[29]  H. Schultheiss,et al.  Procoagulant Soluble Tissue Factor Is Released From Endothelial Cells in Response to Inflammatory Cytokines , 2005, Circulation research.

[30]  T. Wakefield,et al.  Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. , 2005, Blood.

[31]  Nigel Mackman,et al.  Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. , 2004, Blood.

[32]  D. Dixon,et al.  Change in protein phenotype without a nucleus: translational control in platelets. , 2004, Seminars in thrombosis and hemostasis.

[33]  M. Chiariello,et al.  Tissue Factor Binding of Activated Factor VII Triggers Smooth Muscle Cell Proliferation via Extracellular Signal–Regulated Kinase Activation , 2004, Circulation.

[34]  V. Fuster,et al.  Caspase-3 and Tissue Factor Expression in Lipid-Rich Plaque Macrophages: Evidence for Apoptosis as Link Between Inflammation and Atherothrombosis , 2004, Circulation.

[35]  M. Bukrinsky A Hard Way to the Nucleus , 2004, Molecular medicine.

[36]  D. Richel,et al.  Tissue Factor and Cancer Metastasis: The Role of Intracellular and Extracellular Signaling Pathways , 2004, Molecular medicine.

[37]  C. Hack,et al.  Human cell‐derived microparticles promote thrombus formation in vivo in a tissue factor‐dependent manner , 2003, Journal of thrombosis and haemostasis : JTH.

[38]  N. Key,et al.  Elevated Whole-Blood Tissue Factor Procoagulant Activity as a Marker of Restenosis After Percutaneous Transluminal Coronary Angioplasty and Stent Implantation , 2003, Circulation.

[39]  Y. Nemerson,et al.  Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein , 2003, Nature Medicine.

[40]  V. Fuster,et al.  Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity , 2003, Circulation.

[41]  S. Coughlin,et al.  PARticipation in inflammation. , 2003, The Journal of clinical investigation.

[42]  Y. Nemerson,et al.  Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. , 2002, Blood.

[43]  Peter Libby,et al.  Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.

[44]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[45]  J. Brosens,et al.  Interferon-γ Modulates Prolactin and Tissue Factor Expression in Differentiating Human Endometrial Stromal Cells. , 2001, Endocrinology.

[46]  C. Hack,et al.  Cell-derived Microparticles Circulate in Healthy Humans and Support Low Grade Thrombin Generation , 2001, Thrombosis and Haemostasis.

[47]  S. Zahler,et al.  Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. , 2001, Biochemical and biophysical research communications.

[48]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[49]  R. Ross Atherosclerosis is an inflammatory disease , 1999 .

[50]  Y. Asada,et al.  Overexpression of tissue factor pathway inhibitor in aortic smooth muscle cells inhibits cell migration induced by tissue factor/factor VIIa complex. , 1999, Thrombosis research.

[51]  J. Badimón,et al.  Blood-borne tissue factor: another view of thrombosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Freyssinet,et al.  Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. , 1999, Circulation.

[53]  J. Williams,et al.  Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[54]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[55]  T. Luther,et al.  The Dietary Pigment Curcumin Reduces Endothelial Tissue Factor Gene Expression by Inhibiting Binding of AP-1 to the DNA and Activation of NF-κB , 1997, Thrombosis and Haemostasis.

[56]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[57]  V. Fuster,et al.  Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.

[58]  P. Carmeliet,et al.  Role of tissue factor in embryonic blood vessel development , 1996, Nature.

[59]  M. Condorelli,et al.  Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion , 1996, Nature Medicine.

[60]  A. Camm,et al.  Increased monocyte tissue factor expression in coronary disease. , 1995, British heart journal.

[61]  R. Ross,et al.  Cell biology of atherosclerosis. , 1995, Annual review of physiology.

[62]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[63]  R. Terkeltaub,et al.  Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[64]  N. Mackman,et al.  Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites , 1991, The Journal of experimental medicine.

[65]  I W Caras,et al.  Lipid association, but not the transmembrane domain, is required for tissue factor activity. Substitution of the transmembrane domain with a phosphatidylinositol anchor. , 1991, The Journal of biological chemistry.

[66]  J. Bazan,et al.  Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Sadler,et al.  Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. , 1989, The Journal of biological chemistry.

[68]  D. Yansura,et al.  Purification of recombinant human tissue factor. , 1989, Biochemistry.

[69]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[70]  T. Drake,et al.  Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. , 1989, The American journal of pathology.

[71]  J. Niemetz,et al.  Purification of Human Brain Tissue Factor , 1988, Thrombosis and Haemostasis.

[72]  W. Weston,et al.  The Endotoxin‐induced Coagulant Activity of Human Monocytes , 1975, British journal of haematology.

[73]  E. Chargaff,et al.  The biological significance of the thromboplastic protein of blood. , 1946, The Journal of biological chemistry.